MGO One Seven LLC Purchases 2,039 Shares of Zoetis Inc. $ZTS

Key Points

• MGO One Seven LLC increased its stake in Zoetis Inc. by 18.3%, acquiring an additional 2,039 shares, bringing its total holdings to 13,206 shares valued at $2,060,000.
• Zoetis reported quarterly earnings of $1.76 per share, exceeding analysts' expectations of $1.62, with revenues of $2.46 billion, a year-over-year increase of 4.2%.
• The company announced a $0.50 quarterly dividend to be paid on December 2nd, with a dividend yield of 1.4%, reflecting a payout ratio of 34.42%.

MGO One Seven LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 18.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,206 shares of the company's stock after acquiring an additional 2,039 shares during the period. MGO One Seven LLC's holdings in Zoetis were worth $2,060,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. MOKAN Wealth Management Inc. grew its position in shares of Zoetis by 10.2% in the 2nd quarter. MOKAN Wealth Management Inc. now owns 7,933 shares of the company's stock valued at $1,236,000 after acquiring an additional 736 shares during the period. Index Fund Advisors Inc. bought a new position in shares of Zoetis in the 2nd quarter valued at about $621,000. Mitchell Sinkler & Starr PA grew its position in shares of Zoetis by 5.2% in the 2nd quarter. Mitchell Sinkler & Starr PA now owns 2,005 shares of the company's stock valued at $313,000 after acquiring an additional 100 shares during the period. CWM LLC grew its position in shares of Zoetis by 60.6% in the 2nd quarter. CWM LLC now owns 35,922 shares of the company's stock valued at $5,602,000 after acquiring an additional 13,555 shares during the period. Finally, OFI Invest Asset Management grew its position in shares of Zoetis by 28.6% in the 2nd quarter. OFI Invest Asset Management now owns 305,311 shares of the company's stock valued at $47,613,000 after acquiring an additional 67,984 shares during the period. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE ZTS opened at $143.45 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $63.58 billion, a P/E ratio of 24.69, a P/E/G ratio of 2.28 and a beta of 0.90. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The firm has a 50-day moving average price of $148.98 and a two-hundred day moving average price of $154.11.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis's payout ratio is currently 34.42%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Argus reaffirmed a "buy" rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.